Hartmut Döhner

Feb 12, 2024 | onlinelibrary.wiley.com | Keith W Pratz |Brian A. Jonas |Vinod Pullarkat |Michael J. Thirman |Jacqueline Garcia |Hartmut Döhner | +9 more

1 INTRODUCTION Acute myeloid leukemia (AML) is a heterogenous neoplasm characterized by proliferation of immature myeloid cells in bone marrow and peripheral blood, leading to failure of normal hematopoiesis.1 AML is the most common acute leukemia in adults, with a median age at diagnosis of 68 years.

Jan 23, 2024 | nature.com | Jacob Appelbaum |Ing S. Tiong |Stephen B. Ting |Richard Stone |Guillermo Garcia-Manero |Guido Marcucci | +4 more

This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access 251,40 € per year only 20,95 € per issue Rent or buy this article Prices vary by article type from$1.95 to$39.95 Prices may be subject to local taxes which are calculated during checkout Data availability For original, de-identified data and/or computer code (R) for analyses please contact the corresponding author ([email protected])....

May 12, 2023 | thelancet.com | Hartmut Döhner |Daniela Weber |Julia Krzykalla |Walter Fiedler

Background Acute myeloid leukaemia with mutated NPM1 is associated with high CD33 expression and intermediate-risk cytogenetics. The aim of this study was to evaluate intensive chemotherapy with or without the anti-CD33 antibody–drug conjugate gemtuzumab ozogamicin in participants with newly diagnosed, NPM1-mutated acute myeloid leukaemia. Methods This open-label, phase 3 trial was conducted at 56 hospitals in Germany and Austria.